Journal Mobile Options
Table of Contents
Vol. 96, Suppl. 1, 2001
Issue release date: 2001
Section title: Paper
Cardiology 2001;96(suppl 1):3–9
(DOI:10.1159/000049095)

A Comparison of Selected Antihypertensives and the Use of Conventional vs Ambulatory Blood Pressure in the Detection and Treatment of Hypertension

Ebbs D.
Didcot Health Centre, Didcot, UK

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 11/8/2001

Number of Print Pages: 7
Number of Figures: 4
Number of Tables: 2

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: http://www.karger.com/CRD

Abstract

This multicenter, randomized, double-blind, parallel group study was undertaken to determine the effectiveness of selected antihypertensives (doxazosin, amlodipine, enalapril, and bendrofluazide) in maintaining 24-hour control of blood pressure (BP). The predictive value of ambulatory (A)BP versus clinic (C)BP measurements as a method for detecting patients with hypertension was also evaluated. A total of 204 patients were screened and of these 110 were diagnosed as mild to moderately hypertensive with clinic diastolic BP 100–110 mm Hg (≧95 mm Hg in patients with coronary heart disease risk factors). The 4 antihypertensives were all equally effective at controlling BP over 24 h, as shown by 24-hour ABP measurements. The incidence of adverse events was similar for all 4 treatment groups; headache was the most common event, being reported by 22 patients (20%). There was a clinically relevant reduction in total cholesterol for the doxazosin (–15.4 mg/dl) and amlodipine (–11.6 mg/dl) treatment groups in comparison with enalapril and bendrofluazide. Our results from ABP measurements suggest that the antihypertensives studied are effective first-line therapy in the regulation of hypertension and that ABP is a reproducible measure. ABP may also be useful in identifying patients with various types of high BP, for instance those with ‘white coat’ hypertension, enabling more accurate screening and diagnosis.


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 11/8/2001

Number of Print Pages: 7
Number of Figures: 4
Number of Tables: 2

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: http://www.karger.com/CRD


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke, and coronary heart disease. Part II. Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827–838.
  2. Health Survey for England 1996, Vol. 1, London. The Stationery Office, 1998.
  3. Ramsay LE, Williams B, Johnston DG, MacGregor G, Poston L, Potter J, Poulton N, Russell G: Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569–592.
  4. Joint National Committee: Sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 1997;157:2413–2446.
  5. Prasad N, Isles C: Ambulatory blood pressure monitoring: A guide for general practitioners. Br Med J 1996;313:1535–1541.
  6. Guidelines Subcommittee: World Health Organisation/International Study of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151–183.
  7. Santucciu C, Parati G, Ulian L, Omboni S, Mancia G: The difference between clinical ambulatory measured blood pressure and daily monitored pressure does not reflect the ‘white-coat’ effect. Cardiologia 1997;42:1067–1069.
  8. Ford V: A 24-hour tool. Ambulatory blood pressure monitoring. Adv Nurse Pract 1997;5:43–46.
  9. Gibbs CR, Murray S, Beevers DG: The clinical value of ambulatory blood pressure monitoring. Heart 1998;79:115–117.
  10. Staessen JA, Byttebier G, Buntix F, Celis H, O’Brien ET, Fagard R: Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. JAMA 1997;278:1065–1072.
  11. Mezzetti A, Pierdomenico SD, Costantini F, Romano F, Bucci A, Di Goacchino M, Cuccurullo F: White-coat resistant hypertension. Am J Hypertens 1997;10:1302–1307.
  12. Pickering TG: A new role for ambulatory blood pressure monitoring? JAMA 1997;278:1110.
  13. Zanchetti A: Twenty-four hour ambulatory blood pressure evaluation of antihypertensive agents. J Hypertens 1997;15 (suppl):S21–S25.
  14. Kawano Y, Tochikubo O, Watanabe Y, Miyajima E, Ishii M: Doxazosin suppresses the morning increase in blood pressure and sympathetic nervous activity in patients with essential hypertension. Hypertens Res 1997;20:149–156.
  15. Watts RW, Wing LM: A placebo-controlled comparison of diltiazem and amlodipine monotherapy in essential hypertension using 24-hour ambulatory monitoring. Blood Pressure 1998;7:25–30.
  16. Whelton A, Dunne B, Glazer N, Kostis JB, Miller WE, Rector DJ, Tresnewsky ON: Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension. J Hum Hypertens 1992;6:325–331.
  17. Weir MR, Reisin E, Falkner B: Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. TROPHY Study Group. Am J Hypertens 1998;11:914–920.
  18. Grimm RH Jr, Grandits GA, Cutler JA, Stewart AL, McDonald RH, Svendsen K, Prineas RJ, Liebson PR: Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med 1997;157:638–648.
  19. Langdon CG, Packard RS: Doxazosin in hypertension: Results of a general practice study in 4,809 patients. Br J Clin Pract 1994;48:293–298.

    External Resources

  20. Tan KW, Frise SA: Efficacy and tolerability of doxazosin versus enalapril in the treatment of patients with mild-to-moderate hypertension. Clin Ther 1997;19:459–470.

    External Resources

  21. Ames RP, Kiyasu JY: Alpha-1 adrenoceptor blockade with doxazosin in hypertension: Effects on blood pressure and lipoproteins. J Clin Pharmacol 1989;29:123–127.

    External Resources

  22. Daae LN, Westlie L: A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: Effects on blood pressure, serum lipids, and coronary heart disease risk. Blood Pressure 1998;7:39–45.
  23. Parati G, Omboni S, Staessen J, Thijs L, Fagard R, Ulian L, Mancia G: Limitations of the difference between clinic and daytime blood pressure as a surrogate measure of the ‘white-coat’ effect. Syst-Eur investigators. J Hypertens 1998;16:23–29.